The Norwegian prime minister commends research from the Lorens team at BerGenBio and CCBIO
The Norwegian Prime Minister Erna Solberg highlighted CCBIO PI James Lorens and his company BerGenBio in her New Year's Address as an example of excellent cancer research.
Main content
As tradition is, the Norwegian prime minister broadcasted her New Year's Address on national television New Year's Day.听
In her speech, she among other topics spoke听of the need for听individuals to听spur our society forward, and creative minds to听make important breakthroughs in research. She also听mentioned听some of the individual people who had听inspired her. Among them, James Lorens' research group听and BerGenBio:
"Another source of inspiration is James Lorens and the company BerGenBio.听James led a group of researchers at the University of Bergen that developed the technology that BerGenBio is now further developing.听They have recently tested their new cancer drug.听The results for leukaemia were even better than expected. An important breakthrough.听Now the drug will be tested on other forms of cancer.
More and more of us are being diagnosed with cancer. It is tragic to watch cancer breaking down a healthy person. When someone close to us is torn away far too soon.听New and better drugs give cause for hope. They give cancer patients precious extra years with their loved ones.
We want more breakthroughs like this.听This is why the Government has considerably increased funding for research."
You can read
Real translation from "bench to听bedside"
CCBIO Director Lars A. Akslen听congratulates听Jim Lorens and听BerGenBio for being highlighted in the New Years's Address from the prime minister.
"This breakthrough work is very promising and what we听need to solve some of the current challenges in contemporary medical听oncology" Akslen says.
"Also, the industrial efforts represent a model story that听should encourage many more to perform real translation from "bench to听bedside". Jim Lorens, a CCBIO Principal Investigator, is clearly one of听the "founding fathers" of this thinking in our area", Akslen concludes.
The clinical trials听work here in Bergen is significantly supported by Bj酶rn-Tore Gjertsen,听PI and co-director at CCBIO.
Read more here about the Lorens group and the Gjertsen group.
听
听
听
听